MAPT and amyloidosis: In an amyloid mouse model, deletion of Dap12 significantly impairs the formation of microglial barriers around plaques, leading to exacerbated dystrophic neurites adjacent to plaques and increased plaque-associated tau pathology [16], while the overall amyloid burden remains unchanged [17].